miRNA displacement as a promising approach for cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

miRNA displacement as a promising approach for cancer therapy

Published:2017-12-11 Issue:1 Volume:5 Page:e1406432
ISSN:2372-3556
Container-title:Molecular & Cellular Oncology
language:en
Short-container-title:Molecular & Cellular Oncology

Author:

Gilot David¹²³^ORCID,Galibert Marie-Dominique¹²³⁴

Affiliation:

1. CNRS UMR 6290, IGDR, 2 avenue Pr Léon Bernard 35043 Rennes, France

2. Université de Rennes 1, 2 avenue Pr Léon Bernard 35043 Rennes, France

3. Equipe labellisée Fondation ARC, 2 avenue Pr Léon Bernard 35043 Rennes, France

4. CHU Rennes, Génétique Somatique des Cancers, 2 Rue Henri le Guilloux, 35000 Rennes, France

Publisher

Informa UK Limited

Subject

Cancer Research,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23723556.2017.1406432

Reference10 articles.

1. The chemical evolution of oligonucleotide therapies of clinical utility

2. FDA-Approved Oligonucleotide Therapies in 2017

3. A non-coding function of TYRP1 mRNA promotes melanoma growth

4. TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome

5. SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human TYRP1 : Two functions for a single gene?;Pigment Cell & Melanoma Research;2021-02-16

2. LncRNA MCM3AP-AS1 promotes proliferation, migration and invasion of oral squamous cell carcinoma cells via regulating miR-204-5p/FOXC1;Journal of Investigative Medicine;2020-07-19

3. MicroRNA‑126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial‑to‑mesenchymal transition and ERK/MAPK signaling pathway;Oncology Letters;2020-05-29

4. MicroRNA-218 regulates the epithelial-to-mesenchymal transition and the PI3K/Akt signaling pathway to suppress lung adenocarcinoma progression by directly targeting BMI-1;EUR REV MED PHARMACO;2019

5. Targeting Epigenetic Regulators in Cancer to Overcome Resistance to Targeted Therapy;Resistance to Targeted Anti-Cancer Therapeutics;2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3